Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588785 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL18622517 | 0.89 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL26661473 | 0.88 | RAB9A (0.56) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL8102163 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL11593080 | 0.87 | SMN1; SMN2 (0.54) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL4075702 | 0.87 | SMN1; SMN2 (0.54) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL11593077 | 0.87 | RAB9A (0.54) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL7647995 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL27610152 | 0.86 | SMN1; SMN2 (0.51) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A | |
| SCHEMBL14733954 | 0.85 | NPC1 (0.53) | ALDH1A1KDM4ESMN1; SMN2HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400166-A2 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3565484-B1 | COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | CONTRALINE INC (US) | 2024-04-03 | — | — | EP | claimed |
| CN-110627832-A | Preparation method for synthesizing tenofovir alafenamide by oxidation method | 江西农业大学 | 2019-12-31 | — | — | CN | claimed |
| EP-3565484-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2019-11-13 | — | — | EP | claimed |
| US-10167319-B2 | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications | BEN-GURION UNIVERSITY OF NEGEV RESEARCH & DEVELOPMENT AUTHORITY (IL) | 2019-01-01 | — | — | US | claimed |
| WO-2018129369-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. (US) | 2018-07-12 | — | — | WO | claimed |
| US-20180185096-A1 | METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS | Contraline, Inc. | 2018-07-05 | — | — | US | claimed |
| US-9795675-B2 | Light-activatable polymeric nanoparticles | CNC — CENTRO DE NEUROCIÊNCIAS E BIOLOGIA CELULAR (PT) | 2017-10-24 | — | — | US | claimed |
| US-20160220673-A1 | LIGHT-ACTIVATABLE POLYMERIC NANOPARTICLES | CNC - CENTRO DE NEUROCIÊNCIAS E BIOLOGIA CELULAR (PT) | 2016-08-04 | — | — | US | claimed |
| EP-3043782-A1 | LIGHT-ACTIVATABLE POLYMERIC NANOPARTICLES | Centro De Neurociéncias E Biologia Celular (PT) | 2016-07-20 | — | — | EP | claimed |
| WO-2015036939-A1 | LIGHT-ACTIVATABLE POLYMERIC NANOPARTICLES | CNC - CENTRO DE NEUROCIÊNCIAS E BIOLOGIA CELULAR (PT) | 2015-03-19 | — | — | WO | claimed |
| US-20140017169-A1 | CAGED CELL PENETRATING PEPTIDE-POLYMER CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BEN-GURION UNIVERSITY OF NEGEV RESEARCH & DEVELOPMENT AUTHORITY (IL) | 2014-01-16 | — | — | US | claimed |
| EP-2575848-A2 | CAGED CELL PENETRATING PEPTIDE-POLYMER CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Ben-Gurion University of The Negev Research and Development Authority (IL) | 2013-04-10 | — | — | EP | claimed |
| WO-2011151814-A2 | CAGED CELL PENETRATING PEPTIDE-POLYMER CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (IL) | 2011-12-08 | — | — | WO | claimed |
| EP-1833987-A4 | A SINGLE-STEP PLATFORM FOR ON-CHIP INTEGRATION OF BIO-MOLECULES | YEDA RES & DEV (IL) | 2009-03-11 | — | — | EP | claimed |
| EP-1833987-A2 | A SINGLE-STEP PLATFORM FOR ON-CHIP INTEGRATION OF BIO-MOLECULES | Yeda Research and Development Co. Ltd. at The Weizmann Institute of Science (IL) | 2007-09-19 | — | — | EP | claimed |
| WO-2006064505-A2 | A SINGLE-STEP PLATFORM FOR ON-CHIP INTEGRATION OF BIO-MOLECULES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-06-22 | — | — | WO | claimed |
| CN-121569735-A | Plant factory cultivation method for shortening rice growth period based on carbon-nitrogen nutrition regulation | 中国农业科学院都市农业研究所 | 2026-02-27 | — | — | CN | disclosed |
| WO-1991016894-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1991-11-14 | — | — | WO | disclosed |
| WO-1991007087-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF ANTI-LIGANDS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1991-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167319-B2 | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications | PRCP, LNPEP, CLSPN | ALDH1A1 4383/4885KDM4E 3603/4885SMN1; SMN2 3131/4885 |
| US-20140017169-A1 | CAGED CELL PENETRATING PEPTIDE-POLYMER CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | PRCP, LNPEP, CLSPN | ALDH1A1 4383/4885KDM4E 3603/4885SMN1; SMN2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.